Patrys moves forward with ARC grant
Wednesday, 11 November, 2009
University of Melbourne researchers have received a $300,000 grant by the Australian Research Council to further work on Patrys's human antibody cancer treatment, PAT-SM6.
The grant was awarded to Associate Professor Geoff Howlett, Dr Terry Mulhern and Dr Danny Hatters, all located at the Bio21 Institute in Parkville.
PAT-SM6 is a natural human antibody that is being used to target solid tumours and metastases in a range of cancers, including melanoma, pancreatic cancer and gastric cancer.
It has already undergone preclinical trials in animal models where it showed it could reduce the number of tumours that spread from colon to the liver.
The first human trials are scheduled to take place in this calendar year.
Patrys (ASX:PAB) opened at 17c, up 12.9% from Monday's opening price in heavy trading.
Overuse of inhalers can increase heart attack risk
Overuse of reliever inhalers is associated with higher risks of developing and dying from...
Unhealthy Western diet could accelerate cognitive decline
An unhealthy Western-style diet is associated with a faster cognitive decline in people with a...
Cancer drug enters clinical trials based on a false mechanism
A cancer drug currently being tested in patients appears to have entered clinical trials based on...
